Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors
Status: ACTIVE_NOT_RECRUITING
Study type: OBSERVATIONAL
Conditions: Trastuzumab Cardiotoxicity|HER2-Positive Breast Cancer Survivors
Interventions: DEVICE: 2D Echocardiogram|DEVICE: Cardiopulmonary exercise testing and post-CPET cardiac function
Sponsor: Memorial Sloan Kettering Cancer Center